OPKO Health, Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
OPKO Health, Inc. (NASDAQ: OPK) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
OPKO Health's ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck [Yahoo! Finance]
OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck
OPKO Health, Inc. (NASDAQ: OPK) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.